Please login to the form below

Not currently logged in
Email:
Password:

heart attack patients

This page shows the latest heart attack patients news and features for those working in and with pharma, biotech and healthcare.

Amgen and UCB’s Evenity finally approved, but with label warnings

Amgen and UCB’s Evenity finally approved, but with label warnings

But Evenity may increase the risk of heart attack, stroke and cardiovascular death so it’s important to carefully select patients for this therapy, which includes avoiding use in patients who ... The label also notes that doctors should consider

Latest news

  • Novartis withdraws EU filing for canakinumab Novartis withdraws EU filing for canakinumab

    The company has completed a phase 3 study of canakinumab as a treatment to prevent stroke and myocardial infarction (MI) or death in patients who have already suffered a heart attack - ... This showed that injections of canakinumab every three months

  • NHS could save £7bn with greater diagnostics use NHS could save £7bn with greater diagnostics use

    It’s important for all stakeholders that we take every opportunity to rapidly adopt tests which show cost savings and benefit to patients.". ... It found that using the high sensitivity cardiac troponin test to diagnose or rule out heart attack in

  • Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use? Daily Brief: Amgen offers Repatha deals in Europe, will Persephone slash Herceptin use?

    Amgen’s FOURIER reduced heart attack risks by 27%, stroke risks by 21% and coronary revascularisations by 22%, but didn't provide a mortality benefit. ... Herceptin, which could reduce their risk of heart damage while making significant cost-savings

  • CV data sets up Novartis' Ilaris for blockbuster sales CV data sets up Novartis' Ilaris for blockbuster sales

    with a prior heart attack and inflammatory atherosclerosis when added to standard therapy. ... Novartis' chief medical officer Vas Narasimhan is hopeful. "Despite current treatment, about 25% of heart attack survivors will have another cardiovascular

  • New outcomes data could unlock Repatha's potential, says Amgen New outcomes data could unlock Repatha's potential, says Amgen

    In the four-year FOURIER trial - which involved 27, 500 patients - the drug significantly reduced the risk of heart attack, stroke and death in patients with heart disease in patients with ... The findings back up an earlier, smaller study ( GLAGOV),

More from news
Approximately 1 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Proving real-world value Proving real-world value

    Insights reach R&D that ordinarily take years; beta-blockers, for example, found expanded use to control hypertension only after retrospective analysis of four decades of use in heart attack patients.”. ... We create thousands of patient leaflets

  • Patient collaborations

    Published: 21 Nov 2011. AZ’s patient support programme provided holistic support to newly diagnosed heart attack patients. ... Improve discharge information. Maximise adherence to medication. Address psychological health. AstraZeneca also launched a

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Understanding the "Big Picture"

    In this case, of the male patients with ACS, 27% experienced angina and 73% experienced a heart attack. ... This quickly demonstrates that the majority of male patients who experience a heart attack will be found within the non ST-elevated heart attack

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics